Safety and Efficacy of Stereotactic Ablative Radiotherapy for Renal Cell Carcinoma Extracranial Metastases
IJROBP Journal SA-CME activity for May 1, 2017 (Volume 98, Issue 1) explores patient safety and clinical research related to efficacy of stereotactic ablative radiotherapy for management of metastatic renal cell carcinoma.
Visit http://www.redjournal.org/article/S0360-3016(17)30044-5/fulltext to read the related journal article online.
This course is available from April 10, 2017, through 11:59 p.m. Eastern time on April 9, 2019.
This program is designed to meet the interest of radiation oncologists and radiation oncology.
Upon completion of this activity, participants should be able to:
- Justify use of stereotactic ablative radiotherapy in management of metastatic renal cell carcinoma.
- Discuss disease and dosimetric factors that influence local control when employing stereotactic ablative radiotherapy in management of renal cell carcinoma metastases.
- Summarize the recommended dose and fractionation stereotactic ablative radiotherapy regimens for management of renal cell carcinoma metastases.
Steve E. Braunstein, MD, PhD has no financial relationships with a commercial interest.
Raquibul Hannan, MD, PhD has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Journal CME Task Force and CME/MOC Committee had control over the content of this activity.
Disclosure Link: Journal CME Task Force and CME/MOC Committee
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
In order to earn credit for this course, participants must navigate the activity content through the course progress bar on the left.
You must receive a passing score of 80% on the assessment and complete the evaluation in order to receive credit and your certificate.
Upon completion, you may view, print or save your Certificate by clicking the tab.
Click "Start Course" button to proceed.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.